沙利度胺联合VAD方案治疗多发性骨髓瘤临床观察

目的探讨沙利度胺联合VAD方案与单用VAD方案治疗初治多发性骨髓瘤（MM）的临床效果及安全性。方法35例初治MM病人在采用VAD方案治疗的基础上,将沙利度胺从小剂量（100mg/d）开始口服,在能耐受的情况下逐渐增加剂量,一般不超过300mg/d。30例MM病人采用VAD方案治疗。结果沙利度胺联合VAD方案组的有效率优于单用VAD方案组（uc=3.19,P〈0.05）,沙利度胺联合VAD方案组的不良反应有神经毒性、嗜睡、便秘、脱发及感染。结论沙利度胺联合VAD方案治疗初治性MM疗效显著优于VAD方案,缓解率高,是治疗初治性MM效果较好而又安全的方案,应优先考虑使用。

CLINICAL ANALYSIS OF THE EFFICACY OF THALIDOMIDE COMBINED WITH VAD CHEMOTHERAPY FOR MULTIPLE MYELOMA

Objective To compare the efficacy and safety of Thalidomide-combined-with-VAD （combotherapy） chemotherapy and VAD-alone chemotherapy （VAD alone） for multiple myeloma （MM）. Methods Thirty-five cases newly diagnosed MM were enrolled for combotherapy. Thirty patients treated with VAD alone served as controls. Results The response rate in the combotherapy was higher than that in the VAD alone （uc = 3.19, P〈0.05）. The main side reactions in the combotherapy were neurotoxicity, fatigue, lethargy, constipation, alopecie and infection. Conclusion The combotherapy is an effective and safe regimen for newly diagnosed MM and appears significantly superior to VAD alone.